Anavex Life Sciences

Anavex appoints Robert Chisholm as CFO

Friday, June 29, 2012 11:01 AM

Anavex Life Sciences, a pharmaceutical company based in Vancouver, has appointed Robert Chisholm as chief financial officer.

More... »


Anavex successfully completes phase I Alzheimer's trial

Monday, November 14, 2011 11:17 AM

Anavex Life Sciences has successfully completed its phase I single ascending dose (SAD) clinical trial of ANAVEX 2-73, the company's lead drug candidate for the treatment of Alzheimer's Disease.  ANAVEX 2-73 is the first of a new class of oral drugs being studied to potentially treat AD through disease modification rather than focusing only on symptomatic improvement.

More... »


Anavex names executive director

Wednesday, October 12, 2011 11:52 AM

Anavex Life Sciences has named Dr. George Tidmarsh executive director. 

More... »

Anavex continues ANAVEX 2-73 phase I trial

Friday, July 8, 2011 12:24 PM

Anavex Life Sciences has commenced the 30mg dose step in its ongoing phase I clinical trial to evaluate ANAVEX 2-73, a drug candidate for Alzheimer's disease. This is the third of six potential dose steps and follows the successful completion of the 1mg and 10mg dosing rounds.  There have been no adverse effects recorded to date.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.